SFPIA
TVTX icon

Stevens First Principles Investment Advisors’s Travere Therapeutics TVTX Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-700
Closed -$8K – 246
2014
Q2 		$8K Buy
700
+200
+40% +$2.71K ﹤0.01% 189
2014
Q1 		$11K Buy
+500
New +$7.69K 0.01% 175

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Stevens First Principles Investment Advisors's TVTX Position: Q3 2014 in Review

Stevens First Principles Investment Advisors sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 700 shares — an estimated $8K sold.

Stevens First Principles Investment Advisors first reported a position in TVTX in Q1 2014 and held it in 2 quarters. The position peaked at $11K in Q1 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

  • Stevens First Principles Investment Advisors reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 700 Travere Therapeutics shares in Q3 2014, an estimated $8K.
  • Stevens First Principles Investment Advisors first reported a position in Travere Therapeutics in Q1 2014 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's Travere Therapeutics position peaked at $11K in Q1 2014.
  • 60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2014, filed 10 Nov 2014.